What Is Tesamorelin?
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone.
It is based on the full 44-amino-acid GHRH sequence but includes a modification that improves resistance to enzymatic breakdown.
Its primary action is:
stimulating the pituitary gland to release the body’s own growth hormone.
That makes tesamorelin part of the same general GHRH family as sermorelin and Modified GRF 1-29, but its clinical development went much further.
Tesamorelin ultimately became an FDA-approved medication.
Why Are Researchers Interested in It?
Tesamorelin sits at the intersection of several major areas of research:
visceral fat, growth hormone physiology, IGF-1, body composition, liver fat, lipid metabolism, HIV-associated lipodystrophy, and metabolic health.
What makes it especially interesting is that its effects are not just theoretical.
Tesamorelin has been studied extensively in randomized human clinical trials.
Those trials repeatedly demonstrated reductions in visceral abdominal fat.
That gives tesamorelin one of the strongest human evidence bases among peptides used to influence the GH axis.
How Does Tesamorelin Work?
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary.
This stimulates the pituitary to release endogenous growth hormone.
Growth hormone then acts on tissues throughout the body and stimulates production of insulin-like growth factor-1, or IGF-1.
The pathway looks like this:
GHRH receptor activation → GH release → IGF-1 production → downstream metabolic and tissue effects.
Growth hormone has important effects on:
fat metabolism, protein metabolism, muscle biology, liver metabolism, and body composition.
Tesamorelin uses the body’s own pituitary machinery rather than supplying GH directly.
Visceral Fat
The most important established effect of tesamorelin is reduction of visceral adipose tissue.
Visceral fat is the fat stored around internal organs inside the abdominal cavity.
It is metabolically different from the fat immediately beneath the skin.
Higher amounts of visceral fat are associated with:
insulin resistance, inflammation, dyslipidemia, fatty liver, cardiovascular risk, and metabolic disease.
In people with HIV-associated lipodystrophy, excess visceral fat can become especially pronounced.
This is the population in which tesamorelin was developed.
Human Visceral-Fat Research
Tesamorelin has substantial randomized clinical evidence.
In one large study of 404 adults with HIV and excess abdominal fat, visceral adipose tissue fell by approximately 10.9% after six months of tesamorelin treatment compared with approximately 0.6% in the placebo group.
Participants who remained on tesamorelin for 12 months achieved an approximately 18% reduction in visceral adipose tissue.
Another major randomized trial involving 412 participants found visceral fat decreased by about 15.2% with tesamorelin while increasing by about 5% with placebo.
These are meaningful human results.
Why Does Growth Hormone Affect Visceral Fat?
Growth hormone strongly influences fat metabolism.
One of its actions is promoting lipolysis—the release of stored fatty acids from adipose tissue.
Visceral adipose tissue appears particularly responsive to GH signaling.
This helps explain why tesamorelin can reduce central visceral fat without producing identical changes in every fat depot.
In clinical research, reductions in visceral fat occurred without comparable loss of subcutaneous abdominal or limb fat.
That selectivity is one of tesamorelin’s most interesting features.
Is Tesamorelin a Weight-Loss Drug?
No.
This is an important distinction.
Tesamorelin can substantially reduce visceral fat while having relatively little effect on total body weight.
The FDA label specifically states that Egrifta SV is not indicated for weight-loss management and describes the medication as weight neutral.
So someone could potentially lose meaningful visceral fat without seeing a dramatic change on the scale.
Tesamorelin is better understood as a body-composition and visceral-fat therapy than a traditional weight-loss drug.
Waist Circumference & Body Composition
Clinical studies have shown improvements in several measures related to central fat accumulation.
These include:
waist circumference, trunk fat, waist-to-hip ratio, visceral adipose tissue, and patient-reported abdominal appearance.
A recent systematic review and meta-analysis of randomized trials found significant reductions in visceral adipose tissue, waist circumference, and trunk fat while also reporting an increase in lean body mass.
This reinforces the idea that tesamorelin can meaningfully change body composition even when overall weight does not change dramatically.
Liver Fat
Tesamorelin has also generated significant interest in liver-fat research.
A randomized clinical trial involving people with HIV and abdominal fat accumulation found that six months of tesamorelin reduced both visceral fat and liver fat compared with placebo.
The net treatment effect for liver fat was approximately a 2.9 percentage-point reduction.
That finding led to larger and longer studies.
Fatty Liver Research
A subsequent randomized multicenter trial studied people with HIV and nonalcoholic fatty liver disease.
After 12 months, tesamorelin produced approximately a 37% relative reduction in hepatic fat compared with placebo.
About 35% of tesamorelin-treated participants reached a liver-fat fraction below 5%, compared with approximately 4% receiving placebo.
Those findings made liver metabolism one of the most interesting research areas surrounding tesamorelin.
However, reducing liver fat is not currently its FDA-approved indication.
Triglycerides & Lipids
Tesamorelin may also influence lipid metabolism.
In a large randomized study, triglycerides decreased by approximately 50 mg/dL in the tesamorelin group while increasing by about 9 mg/dL with placebo.
The total-cholesterol-to-HDL ratio also improved.
In longer-term research, reductions in triglycerides were maintained during continued treatment.
Some of these improvements may occur because visceral fat itself is metabolically active.
Reducing it can influence broader metabolic signaling.
IGF-1
Because tesamorelin stimulates growth hormone release, it increases IGF-1.
This is expected pharmacology.
IGF-1 participates in:
muscle biology, tissue growth, bone metabolism, cellular signaling, and protein synthesis.
However, excessive IGF-1 activity can also create risks.
For that reason, IGF-1 levels are clinically monitored during treatment with prescription tesamorelin.
The goal is not unlimited stimulation of the GH axis.
It is controlled activation within a defined clinical context.
Tesamorelin vs. Growth Hormone
Tesamorelin does not contain growth hormone.
It stimulates the pituitary to release endogenous GH.
Recombinant human growth hormone supplies GH directly.
This distinction influences physiology.
Because tesamorelin requires the pituitary to respond, endogenous feedback mechanisms remain involved.
The body still has mechanisms such as somatostatin and IGF-1 feedback that can regulate GH secretion.
This makes GHRH-based stimulation different from simply administering GH from outside the body.
Tesamorelin vs. Sermorelin
Both stimulate the GHRH receptor.
Sermorelin is based on the first 29 amino acids of GHRH.
Tesamorelin is based on the full 44-amino-acid GHRH sequence and includes a structural modification designed to improve stability.
Sermorelin has important historical human clinical research and was once marketed as Geref.
Tesamorelin, however, went on to become an FDA-approved contemporary therapy specifically for HIV-associated visceral fat.
So in terms of current pharmaceutical development:
tesamorelin has the stronger modern regulatory and clinical evidence base.
Tesamorelin vs. CJC-1295 No DAC
Modified GRF 1-29, often called CJC-1295 No DAC, is another GHRH analogue.
Like sermorelin, it is based on the first 29 amino acids of GHRH.
It includes substitutions intended to improve peptide stability.
Tesamorelin uses the full 44-amino-acid GHRH backbone and has undergone extensive pharmaceutical development.
That means tesamorelin has far more robust controlled human outcome data.
Tesamorelin vs. CJC-1295 With DAC
True CJC-1295 with DAC contains a drug-affinity-complex modification that allows prolonged albumin binding.
This produces a much longer duration of activity.
Tesamorelin does not use that DAC approach.
Its clinical pharmacology was developed around daily administration and physiologic stimulation of the GH axis.
The two compounds therefore share a receptor target but have very different pharmacokinetic strategies.
Tesamorelin vs. GLP-1 Drugs
Tesamorelin and medications such as semaglutide, tirzepatide, and retatrutide work through completely different systems.
GLP-1-based drugs primarily influence:
appetite, satiety, gastric emptying, glucose regulation, and body weight.
Tesamorelin primarily influences:
the GH/IGF-1 axis and visceral-fat metabolism.
GLP-1 drugs commonly produce substantial total weight loss.
Tesamorelin can reduce visceral fat without substantial total weight loss.
They therefore represent very different approaches to metabolic medicine.
Does the Fat Stay Off?
Not necessarily.
One of the clearest findings from longer-term tesamorelin research is that the effect depends on continued treatment.
Participants who continued tesamorelin maintained substantial visceral-fat reductions.
Those switched from tesamorelin to placebo tended to regain visceral fat.
That tells us the peptide is modifying an active metabolic process rather than permanently eliminating the biological tendency toward visceral fat accumulation.
Glucose & Insulin
Growth hormone can influence glucose metabolism.
This is therefore an important safety consideration.
Clinical studies have often shown relatively modest average changes in glucose measures, but the FDA labeling warns that tesamorelin can cause glucose intolerance or diabetes and recommends monitoring glucose status.
In the six-month liver-fat trial, fasting glucose rose temporarily early in treatment but the difference between tesamorelin and placebo was no longer significant at six months.
Individual responses still matter.
Cancer & IGF-1 Considerations
Growth hormone and IGF-1 participate in cellular growth signaling.
That makes active malignancy an important consideration.
The FDA labeling lists active malignancy as a contraindication and advises careful assessment in patients with a history of malignancy.
This does not mean tesamorelin “causes cancer.”
It means that deliberately increasing GH/IGF-1 signaling deserves caution when abnormal cell growth is already present or clinically relevant.
Fluid Retention
Increased GH activity can lead to fluid-related effects.
These may include:
edema, joint discomfort, muscle discomfort, or carpal-tunnel-type symptoms.
These are known effects of increased growth hormone signaling and are included in prescribing information for tesamorelin.
HIV-Associated Lipodystrophy
Tesamorelin was developed for a very specific clinical problem.
Some people living with HIV—particularly in association with earlier antiretroviral treatment patterns—develop abnormal redistribution of body fat.
This can involve:
loss of peripheral subcutaneous fat, increased abdominal visceral fat, dorsocervical fat accumulation, and other body-composition changes.
Visceral abdominal fat can affect both appearance and metabolic health.
Tesamorelin targets that excess visceral component.
FDA Approval
Egrifta SV is FDA approved for:
reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
The label specifically notes that it is not a general weight-management medication.
Long-term cardiovascular safety has also not been established.
That means its approved role is narrow and clearly defined.
Evidence Snapshot
Mechanism: Strong.
Human GH/IGF-1 evidence: Strong.
Human visceral-fat evidence: Strong, including large randomized Phase 3 trials.
Visceral-fat reduction: Roughly 15–20% in several major studies over six to twelve months.
Human liver-fat research: Encouraging, including randomized controlled trials showing meaningful reductions in hepatic fat.
General weight-loss evidence: Not its role; FDA labeling describes it as weight neutral.
FDA status: Approved as Egrifta SV for excess abdominal fat associated with HIV lipodystrophy.
What Do We Know?
Tesamorelin is one of the best-supported peptides in the entire GH-secretagogue category.
We know it activates GHRH receptors.
We know it increases endogenous GH and IGF-1.
And most importantly, we know from large human clinical trials that it can significantly reduce visceral abdominal fat in the population for which it was developed.
The effect has been reproduced across multiple randomized studies.
Research showing reductions in liver fat makes the compound even more interesting from a metabolic perspective.
What Are Researchers Still Trying to Determine?
Research questions now extend beyond whether tesamorelin can reduce visceral fat.
That has already been established.
Researchers are interested in:
long-term cardiovascular outcomes, liver disease, metabolic consequences of reducing visceral fat, optimal treatment duration, long-term GH/IGF-1 exposure, body-composition effects, and which patients respond most strongly.
There is also interest in whether benefits seen in HIV-associated metabolic disease could teach researchers something about visceral-fat biology in broader populations.
That does not mean those uses are already proven.
But tesamorelin provides a very useful tool for studying selective visceral-fat reduction in humans.
Research & Regulatory Status
Tesamorelin is FDA approved as Egrifta SV for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
It is not FDA approved for:
general obesity, cosmetic fat loss, bodybuilding, anti-aging, athletic performance, ordinary abdominal fat, or general weight management.
It has also been studied for liver-fat reduction in people living with HIV, but liver disease is not its current FDA-approved indication.
Commercial or compounded products marketed outside the approved Egrifta SV context should not automatically be assumed equivalent to the FDA-approved pharmaceutical product.
Your Pep Resource Takeaway
Tesamorelin is a standout peptide because the underlying concept actually translated into meaningful human outcomes.
Researchers started with a simple biological idea:
stimulate the body’s own growth-hormone pathway and use that signaling to influence visceral-fat metabolism.
It worked.
Randomized human trials repeatedly showed meaningful reductions in visceral abdominal fat, and those findings ultimately supported FDA approval.
Tesamorelin has also produced intriguing results involving liver fat, triglycerides, body composition, and metabolic health.
That does not make it a general-purpose weight-loss peptide.
In fact, one of its most interesting qualities is precisely the opposite:
it can substantially alter visceral fat without producing dramatic changes in overall body weight.
For researchers interested in visceral fat, body composition, liver fat, GH, IGF-1, metabolic health, HIV-associated lipodystrophy, and endocrine regulation, tesamorelin has one of the strongest clinical foundations in peptide medicine.
Research Areas / Search Keywords
Tesamorelin, Egrifta, Egrifta SV, growth hormone releasing hormone, GHRH, GHRH analogue, growth hormone releasing factor, GRF, GH peptide, growth hormone peptide, GH secretagogue, pituitary peptide, growth hormone release, endogenous growth hormone, IGF-1, insulin-like growth factor 1, GH axis, GHRH receptor, visceral fat, visceral adipose tissue, VAT, belly fat research, abdominal fat, abdominal visceral fat, deep abdominal fat, central fat, body composition, trunk fat, waist circumference, visceral fat reduction, HIV lipodystrophy, HIV-associated lipodystrophy, HIV abdominal fat, antiretroviral lipodystrophy, metabolic health, metabolic peptide, fat metabolism, lipolysis, liver fat, fatty liver, hepatic fat, hepatic steatosis, NAFLD research, MASLD research, triglycerides, lipid metabolism, lean body mass, growth hormone metabolism, tesamorelin vs sermorelin, tesamorelin vs CJC-1295, tesamorelin vs Modified GRF 1-29, tesamorelin vs HGH, tesamorelin vs semaglutide, tesamorelin vs tirzepatide, tesamorelin weight loss, tesamorelin belly fat, FDA-approved peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Tesamorelin is FDA approved as Egrifta SV specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA approved as a general weight-loss, anti-aging, bodybuilding, or cosmetic fat-loss medication, and FDA labeling states that it is weight neutral rather than a weight-management treatment. Research involving liver fat and other metabolic applications should not be interpreted as an approved indication.